Cargando…

Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes

AIM: Nonadherence to glucagon-like peptide-1 receptor agonists (GLP1 RAs) is relatively common among patients with type 2 diabetes mellitus (T2DM). This study sought to identify reasons why patients discontinue GLP1 RAs. MATERIALS AND METHODS: Retrospective data from the Adelphi Diabetes Disease Spe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sikirica, Mirko V, Martin, Alan A, Wood, Robert, Leith, Andrea, Piercy, James, Higgins, Victoria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630073/ https://www.ncbi.nlm.nih.gov/pubmed/29033597 http://dx.doi.org/10.2147/DMSO.S141235

Ejemplares similares

Non-Persistence and Non-Adherence of Patients with Type 2 Diabetes Mellitus in Therapy with GLP-1 Receptor Agonists: A Retrospective Analysis
por: Wilke, Thomas, et al.
Publicado: (2015)

Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015
por: Higgins, Victoria, et al.
Publicado: (2016)

Comparative cardiovascular effects of GLP‐1 agonists using real‐world data
por: Wallia, Amisha, et al.
Publicado: (2023)

Alignment of Physician-Stated vs Clinically Derived Reference Fibrosis Score in Patients with Non-Alcoholic Steatohepatitis: A Real-World European Survey
por: Anstee, Quentin M, et al.
Publicado: (2023)

Reasons for discontinuing insulin and factors associated with insulin discontinuation in patients with type 2 diabetes mellitus: a real-world evidence study
por: Wu, Jianmin, et al.
Publicado: (2021)

MON-LB028 Comparing Cardiovascular Effects of GLP-1 Agonists in a Real World Setting
por: Wallia, Amisha, et al.
Publicado: (2019)

Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
por: Piccini, Sara, et al.
Publicado: (2023)

Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia
por: Evdoshenko, Evgeniy, et al.
Publicado: (2019)

Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study
por: Zhou, Yu, et al.
Publicado: (2022)

Every reason to discontinue lithium
por: Salgado, Manuel E Fuentes, et al.
Publicado: (2014)

Establishing the relationship of inhaler satisfaction, treatment adherence, and patient outcomes: a prospective, real-world, cross-sectional survey of US adult asthma patients and physicians
por: Price, David, et al.
Publicado: (2015)

Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study
por: Saijo, Yuto, et al.
Publicado: (2023)

1539. Presence of mental health concerns is associated with poor adherence in people taking pre-exposure prophylaxis in real-world clinical practice in the United States
por: Hennessy, Fritha, et al.
Publicado: (2023)

Patient and physician perspectives on alopecia areata: A real‐world assessment of severity and burden in Japan
por: Edson‐Heredia, Emily, et al.
Publicado: (2022)

PM381. Reason for clozapine discontinuation
por: Cho, Jin-Woo, et al.
Publicado: (2016)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS
por: Yang, Zheng, et al.
Publicado: (2022)

FRI078 Real-World Weight Loss Outcomes And Safety Of Tirzepatide, A Novel Dual GIP And GLP-1 Receptor Agonist
por: Fansa, Sima, et al.
Publicado: (2023)

Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review
por: Yang, Chen-Yi, et al.
Publicado: (2021)

Real-World Evaluation of GLP-1 Receptor Agonist Therapy Persistence, Adherence and Therapeutic Inertia Among Obese Adults with Type 2 Diabetes
por: Palanca, Ana, et al.
Publicado: (2023)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

Clinical Trial Highlights – GLP-1 agonists
por: McFarthing, Kevin, et al.
Publicado: (2020)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Reasons given by mothers for discontinuing breastfeeding in Iran
por: Olang, Beheshteh, et al.
Publicado: (2012)

Reasons for discontinuation of radiation therapy and effective countermeasures
por: Maebayashi, Toshiya, et al.
Publicado: (2018)

Adaptive reasoning for real-world problems : a schema-based approach /
por: Turner, Roy M.
Publicado: (1994)

Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence
por: Schechter, Meir, et al.
Publicado: (2023)

Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021
por: Malik, Mariam Elmegaard, et al.
Publicado: (2023)

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States
por: Weiss, Tracey, et al.
Publicado: (2020)

Survey of reasons for discontinuation from in vitro fertilization treatment among couples attending infertility clinic
por: Kulkarni, Grishma, et al.
Publicado: (2014)

Basal Insulin Use With GLP-1 Receptor Agonists
por: Anderson, Sarah L., et al.
Publicado: (2016)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
por: Norborg, Hilde, et al.
Publicado: (2021)

Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis
por: Uchida, Genta, et al.
Publicado: (2023)

Reasons for discontinuation of subcutaneous interferon β-1a three times a week among patients with multiple sclerosis: a real-world cohort study
por: Sabidó-Espin, Meritxell, et al.
Publicado: (2017)

Real-World Impact of Physician and Patient Discordance on Health-Related Quality of Life in US Patients with Acute Myeloid Leukemia
por: Horvath Walsh, L. Elise, et al.
Publicado: (2019)

Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK
por: Weiss, Tracey, et al.
Publicado: (2022)

Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions
por: Anstee, Quentin M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g55gmtdr4c1sicj27uj50fnrj8